GB202100194D0 - Inhibition of T-Cell activity - Google Patents

Inhibition of T-Cell activity

Info

Publication number
GB202100194D0
GB202100194D0 GBGB2100194.6A GB202100194A GB202100194D0 GB 202100194 D0 GB202100194 D0 GB 202100194D0 GB 202100194 A GB202100194 A GB 202100194A GB 202100194 D0 GB202100194 D0 GB 202100194D0
Authority
GB
United Kingdom
Prior art keywords
inhibition
cell activity
activity
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2100194.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GBGB2100194.6A priority Critical patent/GB202100194D0/en
Publication of GB202100194D0 publication Critical patent/GB202100194D0/en
Priority to PCT/EP2022/050213 priority patent/WO2022148816A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2100194.6A 2021-01-07 2021-01-07 Inhibition of T-Cell activity Ceased GB202100194D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2100194.6A GB202100194D0 (en) 2021-01-07 2021-01-07 Inhibition of T-Cell activity
PCT/EP2022/050213 WO2022148816A1 (en) 2021-01-07 2022-01-06 Inhibition of t-cell activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2100194.6A GB202100194D0 (en) 2021-01-07 2021-01-07 Inhibition of T-Cell activity

Publications (1)

Publication Number Publication Date
GB202100194D0 true GB202100194D0 (en) 2021-02-24

Family

ID=74667704

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2100194.6A Ceased GB202100194D0 (en) 2021-01-07 2021-01-07 Inhibition of T-Cell activity

Country Status (2)

Country Link
GB (1) GB202100194D0 (en)
WO (1) WO2022148816A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004729A2 (en) * 2014-09-17 2017-12-05 Merck Patent Gmbh process of treating bone metastasis diseases, medicines for bone metastasis and predicting the clinical outcome of treatment for bone metastasis diseases
AU2018346681B2 (en) * 2017-10-05 2024-02-22 Epivax, Inc. Regulatory T cell epitopes

Also Published As

Publication number Publication date
WO2022148816A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
IL279256A (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
CA207208S (en) Set of earbuds
IL305751A (en) Synthesis of omecamtiv mecarbil
GB201904612D0 (en) Reaction of glycoladehyde
GB202006665D0 (en) Treatment of ischaemia
EP4098258A4 (en) Pharmaceutical use of ketoamide-based compound
EP3908292A4 (en) Improved targeted t-cell therapy for treatment of multiple myeloma
EP4096703A4 (en) Therapeutic uses of tirzepatide
IL308476A (en) Inhibitors of the menin-mll interaction
EP3946435C0 (en) Enhancement of cytolytic t-cell activity by inhibiting ebag9
GB2594955B (en) Seedstocks of Sphagnum
EP4041735A4 (en) Prodrugs of myeloperoxidase inhibitors
GB202100194D0 (en) Inhibition of T-Cell activity
CA207207S (en) Set of earbuds
EP3982954A4 (en) Nt5c2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia
GB201907305D0 (en) Treatment of conditions
GB202107612D0 (en) Inhibitors of metallo-beta-lactamases
GB202103774D0 (en) Detectiion of Ransomware
KR102423280B9 (en) Sot-mram area-optimized design of sot-mram
GB202215264D0 (en) Use of urolithins
GB2597353B (en) Construction of an arch
GB2595725B (en) Feedthrough
GB202101251D0 (en) Treatment of conditions
IL291368A (en) Inhibitor of metadherin expression
ZA202003088B (en) Treatment of tuberculosis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)